Partnerships in Health

The Innovative Health Initiative is a partnership between the European Union and industry associations representing the sectors involved in healthcare. By supporting projects that bring together these industries as well as universities, small and medium-sized enterprises (SMEs), patients, regulators and others, IHI aims to pioneer a new, more integrated approach to health research.

- Type: Institutionalised
- Predecessor: Innovative Medicines Initiative (IMI)
- Strategic Research and Innovation Agenda
- Factsheet IHI

Go to the IHI website

All topics texts, documentation (including a comprehensive guide for applicants) can be found on the IHI website. Calls can also be found on the Funding & Tenders portal.

Swiss entities can participate. For further information, please check here.

Further useful information on IHI Calls can be found on our YouTube Channel.  

The partnership aims to deliver new solutions reducing the burden of infectious diseases in sub-Saharan Africa, and strengthen research capacities for preparedness and response against re-emerging infectious diseases in sub-Saharan Africa and globally.

- Type: Institutionalised
- Predecessor: EDCTP2
- Strategic Research and Innovation Agenda

Go to the EDCTP3 Website
EDCTP3 Factsheet 

Published on the partnership's webpage and the Funding & Tenders portal. 

Swiss entities can participate. For further information, please check here. For further information, please check here on the SERI webpage

The partnership aims to contribute to the transition towards more sustainable, resilient, innovative and high-quality people-centred health and care systems. It will pool a critical mass of European, national and regional scientific resources to more efficiently address similar challenges related to health and care systems transformation.

 

- Type: Co-funded
- Predecessor: The TO-REACH project, Active and Assisted Living (AAL), European Innovation Partnership (EIP) on Active & Healthy Ageing, the Joint Programming “Initiative More Years, Better Lives” (JPI MYBL) 

Go to the THCS Webpage

 Further information on the calls can be found on Innosuisse and SNSF. websites.

This Partnership aims to establish a flexible and much more effective coordination between most funding organisations of the numerous networks established in the European Research Area (ERA) for Health and Well-being. This will be done by centralising those activities that are common or quite similar, while keeping the diversity needed for the scientific development in each of the thematic fields.

- Type: Co-funded
- Predecessor: several ERA-NETs and Joint Programming Initiatives 

Go to the ERA4Health website

Swiss Funding Agency: SNSF participated in the 2024 call but is not a member of the ERA4Health consortium and is not planning to participate in further calls.

The Partnership for the Assessment of Risks from Chemicals aims to develop next-generation chemical risk assessment to protect human health and the environment. It supports the European Union's Chemicals Strategy for Sustainability and the European Green Deal's “Zero pollution” ambition with new data, knowledge, methods and tools, expertise and networks.

- Type: co-funded
- Predecessor: European Joint Programme on human biomonitoring

Go to the PARC website

The present Partnership will not involve open (external) calls for research projects.

The partnership aims to coordinate research in personalised medicine between the EU, EU countries and regions.
Aims
- faster uptake of research and innovation results into clinical practice, secure Europe's position in state-of-the-art healthcare provision
- facilitate a shift from a ‘one size fits all’ approach towards taking into account individual differences and better utilising the accumulating data to manage health, disease and its predisposition
- sustainable health systems and independence in data intensive healthcare'

- Type: Co-funded
- Predecessor: ICPerMed and ERA PerMed 

Go to the EP PerMed website

Swiss Funding Agency: Innosuisse.

The main goal is to improve the life of patients by developing diagnostics and treatments for rare diseases through multidisciplinary research and innovation programmes with all relevant stakeholders. This will increase impact and uptake of research results as well as increase the visibility of EU leadership in rare diseases research.

- Type: Co-funded
- Predecessor: E-Rare-3 ERANET and European Joint Programme on Rare Diseases (EJP RD). The European Rare Diseases Research Alliance (ERDERA) was launched in September 2024. It is coordinated by INSERM, France.

Go to the ERDERA website

Further information can be found on the SNSF website.

The partnership aims to coordinate and align activities and funding between countries as well as with the Commission. It will also facilitate national coherence between different services and ministries with responsibility for the various aspects of AMR (e.g. human health, agriculture, environment, industry, finances). The main goal is to contribute to achieving the objectives of the European One Health Action Plan against AMR and the WHO Global Action Plan on AMR, by reducing the threat of AMR.

- Type: Co-funded
- Predecessor: ERA-Net EXEDRA and the JPIAMR  Partnership planned for end of 2024. 

The Covid-19 pandemic revealed the need for better coordinated EU action to respond to health emergencies. This partnership aims to improve the EU’s preparedness to predict, prevent and respond to emerging infectious health threats by better coordinating funding for research and innovation at EU, national (and regional) level towards jointly agreed objectives and an agreed strategic research and innovation agenda (SRIA). The partnership will contribute to building a coherent European Research Area (ERA) enabling Member States and the European Commission to rapidly and jointly support R&I in pandemic preparedness.

- Type: Co-funded
- Predecessor: None